Your session is about to expire
← Back to Search
Cord Blood Transplantation for Blood Cancers
Study Summary
This trial will study how often neutrophils (a type of white blood cell) engraft after cord blood transplantation, which is when blood from a newborn baby's umbilical cord is used to replace bone marrow.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Find a Location
Who is running the clinical trial?
Media Library
- I don't have a closely matched stem cell donor, or finding one quickly is critical for my health.My leukemia is high-risk or not in its first remission.My AML is high-risk and I am in or near my first complete remission, or beyond it.My leukemia or lymphoma has spread to my brain and is not under control.I am between 18 and 49 years old.I am fully active or restricted in physically strenuous activity but can do light work.I have a blood cancer that requires a stem cell transplant from a donor.I have had a bone marrow transplant with intensive treatment.My non-Hodgkin's lymphoma is aggressive and has not responded to initial treatments, and I haven't had chest radiotherapy or a stem cell transplant.I have a health or mental condition that could make cancer treatment risky for me.My heart, lungs, liver, and kidneys are strong enough for intense treatment.I have acute leukemia with a high number of cancer cells in my blood.My liver tests are higher than normal, possibly needing further evaluation.I don't have a closely matched stem cell donor or finding one quickly is harmful to me.My heart, lungs, liver, and kidneys are strong enough for intense treatment.I am not pregnant, breastfeeding, or have a positive pregnancy test.I have lung issues and need extra oxygen or have low lung function tests.I am between 18 and 49 years old.My heart's pumping ability is below normal, or I am on treatment for heart failure.I have acute leukemia with more than 30% blasts in my bone marrow, or it's my first relapse of AML.My kidney function is reduced with creatinine levels high or clearance low.I am fully active or restricted in physically strenuous activity but can do light work.My chronic myeloid leukemia is in the chronic phase, and treatments like Gleevec haven't worked for me.My blood pressure is not well-controlled, or I need more than 2 medications to control it.I have been cancer-free for over 5 years, except for non-melanoma skin cancer or cervical in-situ carcinoma.I have a fungal infection that is either not under control or I've been treated for less than a month.My myelodysplastic syndrome is classified as moderate to high risk.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To what magnitude is this treatment hazardous to recipients?
"Given the Phase 2 designation, and thus limited safety data but no efficacy evidence, we give this intervention a score of 2."
Are there any available slots for participants in this research?
"Clinicaltrials.gov indicates that this medical research is not currently enrolling participants, as it was posted in November 2005 and updated last on June 23rd 2006. However, there are 2050 other trials actively recruiting patients at the present moment."
Is this experiment open to applicants aged 85 and above?
"According to the conditions of this clinical trial, only those aged between 18 and 49 are eligible for enrollment."
Am I eligible to join this experiment?
"This clinical trial is looking to enrol 20 individuals aged between 18 and 49 who have been diagnosed with myelodysplastic syndromes. Additionally, they must meet the following criteria: Other hematological malignancies if approved by a pipeline meeting on an individual basis; authorised by principal investigator; Acute myeloid leukemia (AML) of high-risk in first complete remission (CR), near first CR (<20% marrow blasts after induction therapy); Chronic myeloid leukemia in chronic phase or had failed Gleevec treatment or were intolerant to it and showed signs of failing other treatments, as well as those with"
Share this study with friends
Copy Link
Messenger